• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypereosinophilic Syndrome Pipeline Review H1 2017

    Hypereosinophilic Syndrome Pipeline Review H1 2017

    • Report Code ID: RW0001799311
    • Category Pharmaceuticals
    • No. of Pages 54
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Hypereosinophilic Syndrome - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H1 2017, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.

    The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 4 respectively.

    Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hypereosinophilic Syndrome - Overview
    Hypereosinophilic Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hypereosinophilic Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
    Bristol-Myers Squibb Company
    GlaxoSmithKline Plc
    Knopp Biosciences LLC
    Kyowa Hakko Kirin Co Ltd
    Stemline Therapeutics Inc
    Hypereosinophilic Syndrome - Drug Profiles
    benralizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dasatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dexpramipexole dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mepolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SL-401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hypereosinophilic Syndrome - Dormant Projects
    Hypereosinophilic Syndrome - Product Development Milestones
    Featured News & Press Releases
    Mar 31, 2017: GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
    Mar 21, 2017: Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers
    Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials
    Jan 04, 2017: Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases
    Dec 14, 2016: Steroid-Sparing Effects of Dexpramipexole in Hypereosinophilic Syndromes (HES) Reported at American Society of Hematology 2016 Annual Meeting
    Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole
    Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hypereosinophilic Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
    Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H1 2017
    Hypereosinophilic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
    Hypereosinophilic Syndrome - Pipeline by Stemline Therapeutics Inc, H1 2017
    Hypereosinophilic Syndrome - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Hypereosinophilic Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Bristol-Myers Squibb Company
    GlaxoSmithKline Plc
    Knopp Biosciences LLC
    Kyowa Hakko Kirin Co Ltd
    Stemline Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hypereosinophilic-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypereosinophilic-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypereosinophilic-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments